RELB and Hodgkins lymphoma: The COG clinical trial AHOD0031 evaluated patients with intermediate-risk HL to try to understand the role of NF-κB pathway proteins such as Rel-B, NIK, and A20, along with cytoplasmic Rel-A and IKK-β.